ArticleActa pharmacologica Sinica2026
MMP14-mediated proteolytic cleavage of LAMC2 domain III fragment drives osimertinib resistance in EGFR-mutant non-small cell lung cancer.
Article in Acta pharmacologica Sinica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Anticancer drug discovery: Embracing the next wave of innovation.Acta pharmacologica Sinica · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acquired resistance to osimertinib remains a critical clinical challenge in EGFR-mutant non-small cell lung cancer (NSCLC), with 40%-60% of progressing patients lacking an identifiable genetic resistance driver. Through quantitative secretomic profiling of paired osimertinib-sensitive and -resistant NSCLC cell lines, we identified laminin subunit γ2 (LAMC2) as markedly enriched in resistant cell secretomes. Single-cell RNA sequencing reanalysis revealed a LAMC2-high drug-tolerant persister subpopulation that expanded under osimertinib pressure, with pseudotime analysis suggesting progressive co-upregulation of LAMC2 and matrix metalloproteinase 14 (MMP14) along the treatment-to-resistance trajectory. Across four independent cohorts, MMP14 exhibited the strongest co-expression with LAMC2 among all metalloproteinases; the two proteins also physically interacted, and their concurrent high expression predicted the worst overall survival. Mechanistically, MMP14 cleaved LAMC2 to release a bioactive Domain III (DIII) fragment harboring EGF-like repeats, which reactivated EGFR/AKT/ERK signaling despite continued osimertinib exposure. Exogenous DIII conferred resistance in sensitive cells, whereas an anti-DIII blocking antibody reversed MMP14-driven resistance in cell lines and patient-derived organoids. The selective MMP14 inhibitor NSC405020 restored osimertinib sensitivity in vitro and suppressed xenograft growth. In residual tumor tissues from neoadjuvant osimertinib-treated patients, non-responders exhibited higher LAMC2/MMP14 co-expression and more prominent spatial exclusion of CD8⁺ T-cells from the tumor core compared with major pathological responders. These findings identify the MMP14-LAMC2-DIII proteolytic axis as a non-genetic resistance mechanism and suggest that MMP14 inhibition or DIII neutralization may represent a rational strategy to overcome acquired osimertinib resistance.
Indexed as
Identifiers
42897224What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.